Summary

The blood testing market was estimated to be growing at a CAGR of 5.2% between the forecast period of 2021-2026. As the number of COVID-19 cases increasing worldwide, governments across the globe are exploring the possibilities of allowing private laboratories to ramp up blood testing. The immediate detection of COVID-19 cases requires the wide availability of diagnostics to control the rapid spread of the virus. In February 2020, the U.S. FDA issued a new policy to expedite the availability of diagnostics. A public health emergency was determined, justifying the authorization of emergency use of in-vitro diagnostics (IVDs) for the diagnosis of COVID-19 which ultimately increases the growth of blood testing market across the world. In December 2020, Abbott announced that it had received the CE Mark for its quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology (blood) test. The IgG antibody test type gives a quantitative result ( that measures the amount of antibodies) and also provides important insights to people as they recover from COVID-19. Additionally, it helps evaluate a person's immune response to a vaccine. In July 2020, PerkinElmer Inc., announced the launch of a dry blood spot based test for SARS-CoV-2 IgG using its GSP/DELFIA platform, enabling processing of up to 5,000 samples per day. Due to these factors, the COVID-19 impact on the market is expected to largely positive.

The blood is the most important factor directly within the circulation system of the body, along with the plasma and serum, which is widely studied for the detection of biomarkers also, especially in cancer for cancer detection and early diagnosis. Laboratory-related published studies have shown that the blood test samples are highly useful, which may contain tumorderived materials, which could serve as potentially valuable screening targets. Diseases such as cancer, cardiovascular diseases account for a vast majority of health spending, which will boost the market in the near future. According to the International Agency for Research on Cancer, lung and breast cancers accounted for 23.1% of the total number of new cases that were diagnosed in 2020. Colorectal cancer was the third-most common cancer, with a prevalence of 1.9 million new cases in 2020, according to the International Agency for Research on Cancer. Moreover, the cancer burden differs by region. Almost half of the cancer cases are registered in Asia, and in Europe, one-quarter of the population is suffering from cancer. As per the World Health Organization (WHO) 2019 fact sheet, globally, an estimated 71 million people had chronic hepatitis C virus infection too. With the diversity of diseases increasing and growing focus toward the development of better treatment options for chronic and infectious diseases, the burden of such diseases drives the blood testing market globally, and is among the major factors, for the same.

Key Market Trends

Glucose Testing is Expected to Hold Significant Share of the Blood Testing Market.

A blood glucose test is used to measure the total amount of glucose in the blood. The symptoms of various disorders like diabetes, usually appear suddenly and are often the reason why blood sugar levels need to be checked. Additionally, the self-testing of blood sugar is an important tool to manage diabetes and prevent complications. The rising prevalence of type I as well as type II diabetes coupled with the growing cases of hereditary diabetes, also supporting the growth of glucose testing segment. Furthermore, the prevalence of diabetes has increased in recent years, and many reports have predicted this prevalence to increase further in the future. For instance, as per 2019 report by the International Diabetes Federation, the global prevalence of diabetes is expected to increase from 9.3% in 2019 to 10.9% by 2045. This will increase the demand for blood glucose testing, which will help the market growth.

The presence of portable glucose meters that can be used by the patients for routine checkups anywhere anytime has resulted in the significant share of this segment. Furthermore, diabetes monitoring is carried out prior to any surgical intervention for the patient with diabetes, which consequently influences the demand for these products. For instance, Bio-Rad Laboratories Inc. offers "D-100 System“, which provides the fastest HbA1c testing with hemoglobin variants detection for diabetes. The device includes "Gold Standard" technology with innovative design and the ease of use to enhance medium to high volume laboratory workflow, and helps to deliver precise and accurate results. Thus, owing to above-mentioned factors the segment is expected to show significant growth over the forecast period.

North American Region Holds the Largest Market Share of the Blood Testing Market

The North American region has acquired the largest market share due to technological advancements such as the introduction of miniaturized diagnostic devices, rendering rapid and accurate test results that have higher market penetration in the region, along with favourable medical insurance policies enhancing the market adoption of products. The United States is the largest market in the North American region. As per as the National Diabetes Statistics Report, 2020, there are approximately 34.2 million people or 10.5% of the United States population who have diabetes. Type 1 diabetes accounts for about 5.2% of all diagnosed cases of diabetes, affecting approximately 1.6 million people in the United States. According to the National Diabetes Statistics Report, 2020, which gave costs till the year 2017, in the United States, in 2017, the total estimated cost of diagnosed diabetes was USD 327 billion. In addition, total direct estimated costs of diagnosed diabetes increased from USD 188 billion in 2012 to USD 237 billion in 2017, and total indirect costs increased from USD 73 billion to USD 90 billion in 2017. Therefore, increasing healthcare expenditure on diabetes along with the rising prevalence of diabetes and other chronic diseases is expected to drive the market in the near future

Competitive Landscape

The market consists of several major players. The companies have implemented certain strategic initiatives, such as a merger, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. The major players are Danaher Corporation, BioRad Laboratories, Thermofisher Scientific, Abbott Laboratories and BioMerieux S.A. Additionally, the key players have been involved in various startegic alliances such as acquisitions, collaborations along with the launch of advanced products to secure the position in the global market. For instance, in April 2020, Thermo Fisher Scientific manufactured ImmunoCAP Specific IgE Stinging Insect Allergen Components were approved by the United States Food & Drug Administration (FDA) for in vitro diagnostic use. It is a blood test that identifies patients' sensitization to specific proteins in insect venom that may cause anaphylaxis and other allergic symptoms.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

ページTOPに戻る

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic Diseases
4.2.2 Rising Demand for Home Healthcare and the Introduction of Advance Technology-enabled Products
4.2.3 Implementation of Favorable Government Initiatives & External Funding for R&D Exercises
4.3 Market Restraints
4.3.1 Stringent Regulatory Approval Process
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Glucose Testing
5.1.2 Lipid Panel Testing
5.1.3 Prostate Specific Antigen (PSA) Testing
5.1.4 Blood Urea Nitrogen (BUN) Testing
5.1.5 Thyroid Stimulating Hormone Testing
5.1.6 Other Types (Direct LDL testing, Testosterone Testing)
5.2 By Methods
5.2.1 Manual Blood Testing
5.2.2 Automated Blood Testing
5.3 By End User
5.3.1 Diagnostic Laboratories
5.3.2 Hospitals
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Baxter International
6.1.3 Becton, Dickinson and Company
6.1.4 BioMerieux SA
6.1.5 BioRad Laboratories
6.1.6 Cepheid Corporation
6.1.7 Danaher Corporation
6.1.8 F. Hoffmann-La Roche AG
6.1.9 Novartis International AG
6.1.10 Thermo Fisher Scientific
6.1.11 Una Health Ltd
6.1.12 Shimadzu
6.1.13 Waters Corporation
6.1.14 PerkinElmer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS